3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Multiple Endocrine Neoplasia Type 2a
1
Lethal Congenital Contracture Syndrome 2
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
23
Carboplatin
6
Pemetrexed
5
Paclitaxel
4
Cisplatin
4
130-nm albumin-bound paclitaxel
3
spartalizumab
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Axitinib
2
Albumin-Bound Paclitaxel
2
trametinib
1
ribociclib
1
osimertinib
1
lenvatinib
1
etoposide phosphate
1
durvalumab
1
dabrafenib
1
cemiplimab
1
binimetinib
1
Vascular Endothelial Growth Factor A
1
Nivolumab
1
Gemcitabine
1
Etoposide
1
Doxorubicin
1
Docetaxel
1
DS-8273a
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Vascular Endothelial Growth Factor A
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled